XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.3
EQUITY (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Warrants Outstanding and Exercisable The following table summarizes the status of warrants and related transactions:
Non-Derivative (Equity) Warrants
Derivative Liabilities Warrants
Total Number of WarrantsWeighted - Average Exercise Price
Balance as of January 1, 2024
49,068,63637,862,92286,931,558$1.12 
Granted (1)
2,500,000 19,400,000 21,900,000 $0.99 
Cancelled/forfeited/expired(416,667)— (416,667)$1.56 
Balance as of September 30, 2024
51,151,96957,262,922108,414,891$1.09 
Exercisable as of September 30, 2024
49,241,96957,262,922106,504,891$1.10 
(1)In July 2024, 19,400,000 warrants were issued in connection with the Term Loans. In February 2024, 1,800,000 warrants were issued in connection with the Debt Exchange. Refer to Note 8 - Debt for more information.
Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions The following assumptions were used for the calculation at date of issuance:
Weighted average stock price$0.60
Weighted average expected stock price volatility87.1%
Expected annual dividend yield0%
Weighted average expected life of warrants
4.8 years
Weighted average risk-free annual interest rate4.0%
Weighted average grant date fair value$0.36
Schedule of Stock Options Outstanding
The following table summarizes the status of stock options and related transactions:
Number of Stock OptionsWeighted-Average Per Share Exercise Price
Issued and Outstanding as of January 1, 202427,653,184 $1.40 
Granted12,954,490 $0.57 
Exercised
(64,999)$0.60 
Cancelled/forfeited/expired(12,888,258)$1.85 
Issued and Outstanding as of September 30, 202427,654,417 $0.80 
Exercisable as of September 30, 202410,587,967 $1.05 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions The following assumptions were used for the calculation at date of grant:
Nine Months Ended September 30,
20242023
Weighted average stock price$0.56$0.51
Weighted average expected stock price volatility86.9%76.9%
Expected annual dividend yield0%0%
Weighted average expected life5.0 years6.0 years
Weighted average risk-free annual interest rate3.6%3.6%
Weighted average grant date fair value$0.21$0.34
Schedule of Components of Share-based Compensation Expense
The components of share-based compensation expense are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock options$982 $712 $2,931 $4,170 
Restricted stock— — 2 293 
Warrants100 344 20 1,267 
Total share-based compensation expense$1,082 $1,056 $2,953 $5,730